SG10202102467RA - Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond - Google Patents

Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Info

Publication number
SG10202102467RA
SG10202102467RA SG10202102467RA SG10202102467RA SG10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA SG 10202102467R A SG10202102467R A SG 10202102467RA
Authority
SG
Singapore
Prior art keywords
conjugating
protein
agent
methods
thiol moiety
Prior art date
Application number
SG10202102467RA
Inventor
Jayme Franklin
xin xin Lin
Jeffrey Gorrell
Timothy Tully
Matthew Hutchinson
Charity Tucker Bechtel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG10202102467RA publication Critical patent/SG10202102467RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10202102467RA 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond SG10202102467RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028679P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
SG10202102467RA true SG10202102467RA (en) 2021-04-29

Family

ID=55163580

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202102467RA SG10202102467RA (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
SG11201700365TA SG11201700365TA (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201700365TA SG11201700365TA (en) 2014-07-24 2015-07-17 Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond

Country Status (15)

Country Link
US (2) US11370838B2 (en)
EP (1) EP3172219A4 (en)
JP (3) JP6956630B2 (en)
KR (1) KR102463267B1 (en)
CN (1) CN106536540A (en)
AR (1) AR101304A1 (en)
AU (2) AU2015294389B2 (en)
BR (1) BR112017001403A2 (en)
CA (1) CA2955007C (en)
IL (1) IL250148B2 (en)
MX (2) MX2017001022A (en)
MY (1) MY198629A (en)
RU (2) RU2744978C2 (en)
SG (2) SG10202102467RA (en)
WO (1) WO2016014360A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6956630B2 (en) * 2014-07-24 2021-11-02 ジェネンテック， インコーポレイテッド Method of conjugating to a thiol moiety in a protein containing at least one trisulfide bond of the drug
EP3580234A1 (en) * 2017-02-08 2019-12-18 Pfizer Inc. Large scale production process for capped and un-capped antibody cysteines and their use in therapeutic protein conjugation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2665353B2 (en) * 1988-09-10 1997-10-22 住商ファーマインターナショナル株式会社 Methods for producing bispecific antibodies
JPH0278699A (en) 1988-09-12 1990-03-19 Green Cross Corp:The Benzoylurea compound-albumin complex
JPH02218700A (en) * 1989-02-17 1990-08-31 Nippon Kayaku Co Ltd Dispecific antibody and adoptive immunity using the same antibody
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ZA955789B (en) 1994-07-15 1996-03-11 Novo Nordisk As A method of converting a hydrophobic derivative of a polypeptide into the native form
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH11124395A (en) 1997-10-16 1999-05-11 Seiwa Kasei Kk Peptide containing cysteine introduced thereinto and its production
SE9802454D0 (en) 1998-07-08 1998-07-08 Pharmacia & Upjohn Ab Production of peptides
WO2000071716A2 (en) 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
JP2004530651A (en) 2000-10-31 2004-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド， ア ボディー コーポレイト Improved protein disaggregation and refolding using high pressure
PT1545613E (en) 2002-07-31 2011-09-27 Seattle Genetics Inc Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040048315A1 (en) 2002-08-28 2004-03-11 Pharmacia Corporation Method for the preparation of growth hormone and antagonist thereof having lower levels of isoform impurities thereof
CA2516455C (en) * 2003-02-20 2012-05-01 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
JP4870569B2 (en) * 2003-11-13 2012-02-08 ハンミ ホールディングス カンパニー リミテッド Protein conjugate using immunoglobulin fragment and method for producing the same
AU2005218642B2 (en) * 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
BRPI0510883B8 (en) * 2004-06-01 2021-05-25 Genentech Inc drug-antibody conjugate compound, pharmaceutical composition, method of manufacturing a drug-antibody conjugate compound, and uses of a formulation, a drug-antibody conjugate and a chemotherapeutic agent, and a combination
ES2344120T3 (en) * 2004-12-29 2010-08-18 Novo Nordisk Health Care Ag METHOD TO PREVENT TRAINING OF POLYPEPTIDE TRISULFIDE DERIVATIVES.
CN103030696B (en) * 2006-05-30 2016-09-28 健泰科生物技术公司 Antibody and immune conjugate and application thereof
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
JP5394246B2 (en) 2007-03-30 2014-01-22 ジェネンテック， インコーポレイテッド Antibodies and immunoconjugates and methods for their use
AR066476A1 (en) * 2007-05-08 2009-08-19 Genentech Inc ANTI-MUC16 ANTIBODIES DESIGNED WITH CYSTEINE AND ANTIBODIES AND PHARMACOS CONJUGAODS
RU2557319C2 (en) 2007-07-16 2015-07-20 Дженентек, Инк. HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
EP2249967B1 (en) * 2008-01-31 2019-03-13 Ingevity South Carolina, LLC Oxidized and maleated derivative composition
WO2009099728A1 (en) 2008-01-31 2009-08-13 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
WO2011041721A1 (en) * 2009-10-02 2011-04-07 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
WO2011109308A1 (en) * 2010-03-02 2011-09-09 Seattle Genetics, Inc. Methods for screening antibodies
CN103282055A (en) * 2010-11-05 2013-09-04 CovX科技爱尔兰有限公司 Anti-diabetic compounds
US9562252B2 (en) * 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
US10344050B2 (en) * 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
CA3111357A1 (en) * 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
KR20150006000A (en) * 2012-05-01 2015-01-15 제넨테크, 인크. Anti-pmel17 antibodies and immunoconjugates
CA2876365A1 (en) * 2012-06-19 2013-12-27 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates
JP6956630B2 (en) * 2014-07-24 2021-11-02 ジェネンテック， インコーポレイテッド Method of conjugating to a thiol moiety in a protein containing at least one trisulfide bond of the drug

Also Published As

Publication number Publication date
RU2017105428A (en) 2018-08-29
EP3172219A4 (en) 2018-04-04
BR112017001403A2 (en) 2017-11-21
KR20170028435A (en) 2017-03-13
MY198629A (en) 2023-09-11
US11370838B2 (en) 2022-06-28
EP3172219A1 (en) 2017-05-31
CN106536540A (en) 2017-03-22
IL250148B2 (en) 2023-03-01
AU2015294389B2 (en) 2021-04-29
US20220372141A1 (en) 2022-11-24
AU2021209196B2 (en) 2023-02-02
RU2021106673A (en) 2021-11-25
CA2955007C (en) 2023-04-11
MX2017001022A (en) 2017-12-20
JP6956630B2 (en) 2021-11-02
RU2017105428A3 (en) 2018-08-29
KR102463267B1 (en) 2022-11-03
JP2023052645A (en) 2023-04-11
AU2021209196A1 (en) 2021-08-19
JP2017526652A (en) 2017-09-14
JP2021046419A (en) 2021-03-25
IL250148B (en) 2022-11-01
MX2022012589A (en) 2022-11-09
RU2744978C2 (en) 2021-03-17
IL250148A0 (en) 2017-03-30
AR101304A1 (en) 2016-12-07
WO2016014360A1 (en) 2016-01-28
US20170209593A1 (en) 2017-07-27
JP7219256B2 (en) 2023-02-07
CA2955007A1 (en) 2016-01-28
SG11201700365TA (en) 2017-02-27
AU2015294389A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
IL261188A (en) Antibodies to tigit
IL290457A (en) Antibodies and conjugates thereof
IL254108A0 (en) Amatoxin-antibody conjugates
IL250819A0 (en) Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
ZA201607385B (en) Anti-ptk7 antibody-drug conjugates
DK3119885T3 (en) Antibody-fynomer conjugates
ZA201701337B (en) Conjugates and conjugating reagents
EP3129357C0 (en) Affinity medicant conjugates
DK3148591T3 (en) Nanoparticle-drug conjugates
GB201513607D0 (en) Pyrrolobenzodiazepine-antibody conjugates
IL253549B (en) Antibody-urease conjugates for therapeutic purposes
GB201504694D0 (en) Covalent conjugates
IL250148A0 (en) Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
HK1257229A1 (en) Cck2r-drug conjugates
GB2554027B (en) Glue compositions and methods
GB201620828D0 (en) Compositions of antibody construct-agonist conjugates and methods thereof
GB201518839D0 (en) Conjugates
GB201513605D0 (en) Pyrrolobenzodiazepine-antibody conjugates
FR3022492B1 (en) PNEUMATIC IN TWO PARTS SUITABLE FOR RECHAPING
GB201418986D0 (en) Novel conjugates and novel conjugating reagents
UA29483S (en) BALL JOINT FINGER
UA29250S (en) BALL JOINT FINGER
UA26904S (en) BALL JOINT FINGER
UA29219S (en) BALL JOINT FINGER
UA29116S (en) BALL JOINT FINGER